These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27443592)

  • 41. Immunization with the RTS,S/AS malaria vaccine induces IFN-γ(+)CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge.
    Schwenk R; Lumsden JM; Rein LE; Juompan L; Kester KE; Heppner DG; Krzych U
    Vaccine; 2011 Nov; 29(48):8847-54. PubMed ID: 21983360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RTS,S/AS01
    Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
    Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spatiotemporal Dynamic of the RTS,S/AS01 Malaria Vaccine Target Antigens in Senegal.
    Diallo MA; L'Ollivier C; Diongue K; Badiane AS; Kodio A; Tall ML; Sy M; Seck MC; Sene D; Ndiaye M; Fall FB; Ranque S; Ndiaye D
    Am J Trop Med Hyg; 2021 Oct; 105(6):1738-1746. PubMed ID: 34634772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally.
    Pringle JC; Carpi G; Almagro-Garcia J; Zhu SJ; Kobayashi T; Mulenga M; Bobanga T; Chaponda M; Moss WJ; Norris DE
    Sci Rep; 2018 Apr; 8(1):6622. PubMed ID: 29700348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
    Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
    J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
    Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
    Front Immunol; 2021; 12():641421. PubMed ID: 33815393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
    Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
    Elife; 2022 Jan; 11():. PubMed ID: 35060479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of the RTS,S/AS malaria candidate vaccine.
    Vekemans J; Leach A; Cohen J
    Vaccine; 2009 Dec; 27 Suppl 6():G67-71. PubMed ID: 20006143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Chaudhury S; MacGill RS; Early AM; Bolton JS; King CR; Locke E; Pierson T; Wirth DF; Neafsey DE; Bergmann-Leitner ES
    Vaccine; 2021 Feb; 39(6):968-975. PubMed ID: 33431225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.
    Zhang M; Kaneko I; Tsao T; Mitchell R; Nardin EH; Iwanaga S; Yuda M; Tsuji M
    Malar J; 2016 Apr; 15():201. PubMed ID: 27068454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
    Bergmann ES; Ballou RW; Krzych U
    Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.
    Stanisic DI; Fink J; Mayer J; Coghill S; Gore L; Liu XQ; El-Deeb I; Rodriguez IB; Powell J; Willemsen NM; De SL; Ho MF; Hoffman SL; Gerrard J; Good MF
    BMC Med; 2018 Oct; 16(1):184. PubMed ID: 30293531
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From human antibody structure and function towards the design of a novel Plasmodium falciparum circumsporozoite protein malaria vaccine.
    Wardemann H; Murugan R
    Curr Opin Immunol; 2018 Aug; 53():119-123. PubMed ID: 29751213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
    Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
    Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.
    Wang R; Richie TL; Baraceros MF; Rahardjo N; Gay T; Banania JG; Charoenvit Y; Epstein JE; Luke T; Freilich DA; Norman J; Hoffman SL
    Infect Immun; 2005 May; 73(5):2863-72. PubMed ID: 15845492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi.
    Khan S; Parrillo M; Gutierrez AH; Terry FE; Moise L; Martin WD; De Groot AS
    Hum Vaccin Immunother; 2020; 16(2):214-227. PubMed ID: 30614773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
    McConkey SJ; Reece WH; Moorthy VS; Webster D; Dunachie S; Butcher G; Vuola JM; Blanchard TJ; Gothard P; Watkins K; Hannan CM; Everaere S; Brown K; Kester KE; Cummings J; Williams J; Heppner DG; Pathan A; Flanagan K; Arulanantham N; Roberts MT; Roy M; Smith GL; Schneider J; Peto T; Sinden RE; Gilbert SC; Hill AV
    Nat Med; 2003 Jun; 9(6):729-35. PubMed ID: 12766765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.